Cervical Local Immune Response for High-Risk Human Papillomavirus Infection: Involvement With Cervical Mucus SLPI Proteins

Creative Commons License

Sahin E., MADENDAĞ Y., SAHIN M. E., MADENDAG I. C., AÇMAZ G., Karakukcu C., ...More

CANCER CONTROL, vol.25, no.1, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 25 Issue: 1
  • Publication Date: 2018
  • Doi Number: 10.1177/1073274818798598
  • Journal Name: CANCER CONTROL
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Keywords: cervical immune response, human papillomavirus, high-risk HPV, LGSIL, HGSIL, secretory leukocyte protease inhibitor (SLPI), LEUKOCYTE PROTEASE INHIBITOR, CANCER, EXPRESSION, INDUCTION
  • Erciyes University Affiliated: Yes


Purpose: To evaluate cervical mucus secretory leukocyte protease inhibitor (SLPI) concentrations in patients with high-risk human papillomavirus (hrHPV) 16 or 18 positive and low-grade squamous intraepithelial lesions (LGSIL) or high-grade squamous intraepithelial lesions (HGSIL).